Venus Medtech (Hangzhou) Inc. disclosed in its Monthly Return for Equity Issuer that no changes occurred in its share capital structure during September 2026.

Key figures • Authorised/registered share capital: 441.01 million H-shares and 1,208 unlisted foreign shares, each with a par value of RMB 1. • Issued H-shares (excluding treasury): 441.01 million; issued unlisted foreign shares: 1,208. • Treasury shares: nil movement during the month; total treasury balance remains zero.

Share-based incentives • The Share Option Scheme reported no outstanding, granted, exercised, or lapsed options as at 30 September 2026. • Up to 44.10 million H-shares remain available for future grants under the scheme. • No warrants, convertibles, or other share-issuance agreements were outstanding or exercised.

Repurchase status • The company still holds 3.11 million H-shares repurchased in December 2021 that await formal cancellation; no additional repurchases or cancellations occurred in September.

Public float compliance • Venus Medtech confirmed its public float exceeded the Main Board’s minimum threshold of 25 % of issued H-shares as at 30 September 2026.

Governance and regulatory filings • The board affirmed that all required authorisations, filings, and regulatory conditions related to past share issues or treasury movements have been met.

Bottom line September 2026 saw no equity dilution or treasury activity for Venus Medtech, leaving its share capital unchanged and its public float fully compliant with Hong Kong listing requirements.